Align Technology Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and volume growth were broad-based, with strong results in both teen and adult segments and double-digit DSO expansion. Growth is driven by active conversion, new products, and emerging markets, while ASP is impacted by mix. The company maintains a strong balance sheet and expects stable, mid-single-digit growth in 2026.
-
Market stability in North America supports steady growth, while Europe and APAC see strong double-digit expansion due to under-penetration and new products. Product innovation, especially zero refinement cases, and operational efficiencies are driving higher utilization and margin expansion.
Fiscal Year 2025
-
Q4 and full year 2025 saw record revenues and strong clear aligner volume growth, driven by international markets and DSOs, with margins and EPS exceeding expectations. 2026 guidance projects 3–4% revenue growth and continued margin improvement, with innovation and digital adoption as key drivers.
-
The event highlighted new aligner products, including a no-refinement option, and the upcoming launch of direct fabrication technology. Strong margin improvements are expected from product mix and cost actions, with regional growth led by DSOs and international expansion.
-
U.S. and international markets show stable or accelerating growth, with DSOs and new products driving adoption. China’s VBP policy is expected to narrow price gaps and boost clear aligner volume, while portfolio innovation focuses on zero-refinement options and direct fabrication, supporting future expansion.
-
Global leadership in clear aligners is reinforced by advanced technology, regional manufacturing, and a flexible product portfolio. Growth is driven by DSO expansion, targeted marketing, and new product rollouts, while operational efficiencies and margin improvements are prioritized for 2026.
-
Year-over-year growth was broad-based across most regions, driven by new products, increased doctor engagement, and active conversion strategies. Product innovation and flexible scanner adoption models support volume growth, while premium pricing and a focus on converting traditional cases remain central. DSOs and local marketing are key to future expansion.
-
Q3 2025 saw 1.8% year-over-year revenue growth, led by strong international clear aligner demand and double-digit DSO growth, while North America retail remained mixed. Non-GAAP operating margin rose to 23.9%, and new digital workflow innovations were launched. Q4 and 2025 guidance project continued margin improvement and mid-single digit aligner volume growth.
-
Expanded product flexibility and new pricing models aim to make clear aligners more accessible and competitive with traditional orthodontics. Financing initiatives and strong R&D investment support growth, while regional performance is mixed and competition is consolidating.
-
Revenue growth for 2024 is revised down due to lower volumes in Western markets, but recovery is expected in Q4 from seasonal trends and new products. Innovation in direct fabrication and operational streamlining support margin goals, while the teen market and restorative cases offer significant growth potential.
-
Q2 saw less sequential growth than expected, with interest rates impacting patient conversion and financing. Q4 is expected to improve due to seasonality, new products, and cost initiatives. Emerging markets and DSOs are driving double-digit growth, while product mix shifts may lower ASPs but support margins.
-
Q2 2025 revenues were $1.012B, up sequentially but down year-over-year, with Systems and Services growth offset by Clear Aligner softness. Macroeconomic headwinds and patient hesitation led to lower case conversions, prompting restructuring actions and revised guidance for the remainder of 2025.
-
The event highlighted a new phase of innovation, including AI-driven software and direct printing, and detailed strong growth strategies in EMEA through tailored market approaches and a successful peer-to-peer mentorship program. Recent product launches and next-gen software are driving efficiency and adoption.
-
The conference highlighted strong double-digit growth in APAC and EMEA, stable North American performance, and the impact of new products like IPE and MAOB in expanding market segments. Operational efficiencies and automation are supporting margin expansion, while direct fabrication is expected to be accretive by 2027.
-
Strong Q1 results were driven by broad-based growth and innovation in digital workflows and 3D printing. The updated long-range plan targets accelerated growth post-2028, supported by new products, emerging market expansion, and a doctor-focused strategy.
-
The event outlined a strategy to make digital tooth movement the global standard, leveraging AI, 3D printing, and a broadening product portfolio to drive growth across ortho, GP, and DSO channels. Financial guidance targets 3.5%-5.5% revenue growth in 2025 and 5%-15% annually through 2028, with ongoing investments in innovation and operational efficiency.
-
Q1 2025 saw strong Clear Aligner volume growth, especially in teens and kids, with revenues and margins in line with guidance despite FX and ASP headwinds. Guidance calls for sequential growth in Q2 and mid-single-digit Clear Aligner volume growth for FY2025, with continued innovation and DSO channel strength.
Fiscal Year 2024
-
Q4 and full-year 2024 saw revenue and volume growth, with strong performance in Systems and Services and international markets. FX headwinds and potential tariffs pose risks, but new product launches and investments support a positive outlook for 2025.
-
Recurring revenue from scanner leasing and services is rising, supported by expanded financing and a growing product portfolio. Strong adoption of new digital tools and manufacturing innovation are driving growth, especially in underpenetrated markets like China and the teen segment.
-
Market stability varies by region, with growth in teens and new products driving performance. Operational flexibility in manufacturing and a focus on doctor-led treatment position the business well against competitors and potential trade policy changes. Sequential improvement is expected in Q4, with mid-single digit growth as a baseline for 2025.
-
Strong growth in Asia and emerging markets offset weaker U.S. and Europe, with new products like Lumina and IPE driving future expansion. Margin management and organizational simplification support profitability, while capital allocation remains focused on growth and shareholder returns.
-
Management remains focused on long-term growth, balancing investments with margin discipline amid challenging market conditions. Recovery is seen in several international markets, with technology innovations like Direct Fab and iTero Lumina set to drive future growth and efficiency.
-
Q3 2024 saw 1.8% revenue growth year-over-year, driven by strong international performance and systems and services, but offset by U.S. market weakness and seasonality. Restructuring actions and investments in technology are expected to support margin accretion in 2025.
-
The global orthodontics market is stable, with strong growth opportunities in the teen segment and new product innovations like the Invisalign Palatal Expander and iTero Lumina scanner. ASPs are expected to remain flat to slightly down, while flexible financial strategies and expanded doctor programs support adoption and margin growth.
-
Q2 2024 saw revenue growth of 2.6% year-over-year, driven by higher clear aligner volumes and strong Systems and Services performance, though ASPs declined due to FX and product mix. FY 2024 revenue growth is expected at 4%-6%, with non-GAAP operating margin above 2023.
-
Strong Q1 results and new product launches led to raised revenue guidance, with both clear aligner and systems/services segments contributing. Lumina scanner and Invisalign Palatal Expander are driving innovation, while margin and cash flow improvements support ongoing investments and partnerships.
-
The event highlighted major innovations in dental aligners, including the launch of the iTero Lumina scanner and direct 3D printing of aligners, driving efficiency and expanding treatment capabilities. Strong Q1 results and raised full-year guidance reflect stable markets and successful new product adoption.